Report
Pharmaceuticals: Feedback ESMO – Part III – Last day
PharmaceuticalsFeedback ESMO – Part III – Last day
IMvigor130: Tecentriq not yet practice-changing
Most of the benefit driven by BRCA-2 mutations in PROFOUND
Continuing good signs of activity with monalizumab and IPH5401
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.